Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).

BORIS DOI
Publisher DOI
PubMed ID
37035486
Description
Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 vaccine (98.1% [95% CI, 95.9%-100.0%]) in individuals with different levels of immunosuppression (difference, -2.8% [95% CI, -6.8% to 1.3%]).
Date of Publication
2023-04
Publication Type
Article
Subject(s)
600 - Technology::610 - Medicine & health
Keyword(s)
HIV Organ transplant SARS-CoV-2 Vaccine randomized trial
Language(s)
en
Contributor(s)
Griessbach, Alexandra
Chammartin, Frédérique
Abela, Irene A
Amico, Patrizia
Stoeckle, Marcel P
Hasse, Barbara
Braun, Dominique L
Schuurmans, Macé M
Müller, Thomas F
Tamm, Michael
Audigé, Annette
Mueller, Nicolas J
Günthard, Huldrych F
Koller, Michael T
Trkola, Alexandra
Epp, Selina
Amstutz, Alain
Schönenberger, Christof M
Taji Heravi, Ala
Kusejko, Katharina
Bucher, Heiner C
Briel, Matthias
Speich, Benjamin
Additional Credits
Universitätsklinik für Infektiologie
Series
Open Forum Infectious Diseases
Publisher
Oxford University Press
ISSN
2328-8957
Access(Rights)
open.access
Show full item